Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

715 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Santoni M, Massari F, Bracarda S, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N. Santoni M, et al. Among authors: massari f. Eur Urol Focus. 2022 Nov;8(6):1696-1702. doi: 10.1016/j.euf.2022.02.004. Epub 2022 Feb 19. Eur Urol Focus. 2022. PMID: 35193819
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Iacovelli R, Cartenì G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Cerbone L, Procopio G. Iacovelli R, et al. Among authors: massari f. Eur J Cancer. 2013 Jun;49(9):2134-42. doi: 10.1016/j.ejca.2013.02.032. Epub 2013 Mar 18. Eur J Cancer. 2013. PMID: 23518211
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. Santoni M, et al. Among authors: massari f. Cancer Metastasis Rev. 2014 Mar;33(1):321-31. doi: 10.1007/s10555-013-9453-5. Cancer Metastasis Rev. 2014. PMID: 24337954 Review.
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M, De Giorgi U, Trementino L, Procopio G, Tortora G, Cascinu S. Santoni M, et al. Among authors: massari f. Int J Cancer. 2015 Jan 1;136(1):1-10. doi: 10.1002/ijc.28715. Epub 2014 Feb 7. Int J Cancer. 2015. PMID: 24415642 Free article. Review.
CXC and CC chemokines as angiogenic modulators in nonhaematological tumors.
Santoni M, Bracarda S, Nabissi M, Massari F, Conti A, Bria E, Tortora G, Santoni G, Cascinu S. Santoni M, et al. Among authors: massari f. Biomed Res Int. 2014;2014:768758. doi: 10.1155/2014/768758. Epub 2014 May 29. Biomed Res Int. 2014. PMID: 24971349 Free PMC article. Review.
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Alesini D, Zustovich F, Fraccon AP, Vicario G, Conteduca V, Maines F, Galligioni E. Caffo O, et al. Among authors: massari f. BJU Int. 2015 May;115(5):764-71. doi: 10.1111/bju.12857. Epub 2014 Oct 8. BJU Int. 2015. PMID: 24988879
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Santoni M, et al. Among authors: massari f. J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18. J Urol. 2015. PMID: 25046616
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.
Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. Bria E, et al. Among authors: massari f. Crit Rev Oncol Hematol. 2015 Jan;93(1):50-9. doi: 10.1016/j.critrevonc.2014.08.001. Epub 2014 Aug 18. Crit Rev Oncol Hematol. 2015. PMID: 25195095 Review.
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
Iacovelli R, Farcomeni A, Sternberg CN, Cartenì G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Maria Ruggeri E, Berruti A, Procopio G. Iacovelli R, et al. Among authors: massari f. J Urol. 2015 Jun;193(6):1905-10. doi: 10.1016/j.juro.2014.11.092. Epub 2014 Nov 26. J Urol. 2015. PMID: 25433306
715 results